LOGEX announced on March 1 an investment from Thoma Bravo, a leading software investment firm. LOGEX’s existing shareholders, the company’s founders and Summa Equity will remain invested with the business and will work closely with Thoma Bravo and the executive committee to support LOGEX’s European growth and further drive innovation in healthcare analytics.
This marks Thoma Bravo’s inaugural investment by its European team. Jefferies LLC served as the exclusive financial advisor to LOGEX and Allen & Overy served as legal counsel. Kirkland & Ellis LLP served as legal counsel to Thoma Bravo and Harris Williams LLC served as Thoma Bravo’s exclusive financial advisor.
LOGEX is a healthcare analytics provider which uses data to help healthcare providers and hospitals make better decisions and deliver optimum health outcomes for patients while reducing costs. Founded in 2008 and headquartered in Amsterdam, LOGEX is active in 10 countries with the ambition to further expand across Europe.
Thoma Bravo is a private equity investment firm building on a 30-plus year history of providing equity and strategic support to experienced management teams and growing companies. As of September 30, 2022, it has more than $120 billion in assets under management. Thomas Bravo has offices in Chicago, Miami and San Francisco.
According to data captured in the LevinPro HC database, this acquisition represents the 44th eHealth deal of 2023, and the tenth in the analytics subsector. By comparison, there were 82 eHealth and 17 analytics transactions announced between January 1, 2022, and March 1, 2022.
